4706-74-5

Usage

Uses

Used in Pharmaceutical Research:
2-(piperidin-1-ylmethyl)-3,4-dihydronaphthalen-1(2H)-one is used as a key intermediate in the synthesis of new drugs, targeting a range of medical conditions. Its complex molecular structure allows for the creation of biologically active compounds with potential therapeutic applications.
Used in Drug Development:
In the pharmaceutical industry, 2-(piperidin-1-ylmethyl)-3,4-dihydronaphthalen-1(2H)-one is utilized as a starting material for the development of innovative medications. Its unique properties contribute to the design of drugs with improved efficacy and reduced side effects, enhancing patient outcomes.
Used in Medicinal Chemistry:
2-(piperidin-1-ylmethyl)-3,4-dihydronaphthalen-1(2H)-one serves as a valuable component in the field of medicinal chemistry, where it is employed in the design and synthesis of novel therapeutic agents. Its presence in these compounds can influence their pharmacokinetic and pharmacodynamic properties, making it a crucial element in the development of effective treatments.

Upstream product

• 646-06-0 1,3-DIOXOLANE 
• 6091-44-7 piperidine hydrochloride 
• 529-34-0 3,4-dihydronaphthalene-1(2H)-one 
• 50-00-0 formaldehyd 

Relevant academic research and scientific papers

A modified Mannich reaction using 1,3-dioxolane

Mannich reaction of ketones using 1,3-dioxolane instead of formaldehyde, paraformaldehyde, or 1,3,5-trioxane afforded the corresponding Mannich bases in high yields. Under the same conditions the aminomethylation of aromatics did not proceed but the intramolecular aminomethylation, like a Pictet-Spengler type reaction, proceeded smoothly.

Synthesis of conformationally restricted relatives of the mevinic acids

Condensations between the tricyclic ketones 9, 19 and 23 and the sodio-lithio dianion of methyl acetoacetate lead to the conformationally restricted Mevinic acid relatives 12b, 20b and 26 respectively, following lactonization and selective reduction. The approach of the nucleophile is stereospecific in the first two instances but not in the last; explanations for this behaviour are given. The target compounds showed negligible HMGCoA reductase antagonism.

Analgesic and tranquilizing activity of 5,8 disubstituted 1 tetralone Mannich bases

5,8-Disubstituted 1-tetralone Mannich bases represent semirigid variants of classical (i.e., chlorpromazine) neuroleptic agents. 8-Chloro-5-methoxy-2- morpholinomethyl-1-tetralone exhibits neuroleptic potency in the thiothixene range in animal models. Of greater potential interest, however, is the analgesic potency of the 8-chloro-5-methoxy-2-pyrrolidinomethyl analogue which was in the morphine range. This compound did not induce tolerance nor was its activity reversed by naloxone. Structure-activity relationships of the series are discussed.